Improved method of recombinant AAV2 delivery for systemic targeted gene therapy

Area of Science:

• Gene Therapy
• Biotechnology
• Viral Vector Delivery

Background:

• Gene therapy faces challenges with low transduction efficiency in target tissues.
• Achieving therapeutic transgene expression requires high vector transduction rates.
• Current methods often struggle to deliver sufficient vector to desired locations.

Purpose of the Study:

• To develop a novel method for enhanced recombinant adeno-associated virus 2 (rAAV) vector delivery.
• To improve vector transduction efficiencies for gene therapy applications.
• To investigate microsphere conjugation as a strategy for increased vector concentration and exposure time.

Main Methods:

• Developed rAAV vectors reversibly conjugated to microspheres.
• Conducted in vitro experiments to compare transduction efficiency of free vs. microsphere-bound vector.
• Utilized magnetic microspheres for targeted delivery.
• Performed in vivo studies administering vector intramuscularly and intravenously.

Main Results:

• Microsphere conjugation achieved the same transduction levels as free vector using only 1% of the vector amount.
• Magnetic microspheres enabled targeted delivery of the vector.
• In vivo studies showed higher transduction efficiencies with microsphere-mediated delivery compared to free vector.
• Demonstrated targeted transgene expression through microsphere retention in capillary beds.

Conclusions:

• Microsphere conjugation is a novel and effective method for delivering rAAV vectors.
• This approach significantly enhances vector transduction efficiency and allows for targeted gene expression.
• Microsphere-mediated delivery presents a promising alternative for virus-mediated human gene therapy.